Receptor conformations involved in dopamine D 2L receptor functional selectivity induced by selected transmembrane-5 serine mutations

Molecular Pharmacology

Volumn 81, Issue 6, 2012, Pages 820-831

  Fowler, J Corey ^b   Bhattacharya, Supriyo ^c   Urban, Jonathan D ^b   Vaidehi, Nagarajan ^c   Mailman, Richard B ^a,b  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENYLATE CYCLASE; ALANINE; ARACHIDONIC ACID; DIHYDREXIDINE; DOPAMINE; DOPAMINE 2 RECEPTOR; GUANOSINE 5' O (3 THIOTRIPHOSPHATE); MEMBRANE PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE 1; QUINPIROLE; SERINE;

ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN PHOSPHORYLATION;

ANIMALS; CHO CELLS; CRICETINAE; CRICETULUS; GUANOSINE 5'-O-(3-THIOTRIPHOSPHATE); LIGANDS; MUTATION; PROTEIN CONFORMATION; RADIOLIGAND ASSAY; RECEPTORS, DOPAMINE D2; SERINE;

EID: 84861419372     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.111.075457     Document Type: Article

References (52)

1. Ballesteros JA and Weinstein H (1995) Integrated methods for the construction of three-dimensional models and computational probing of structure-function relations in G protein-coupled receptors. Methods Neurosci 25:366-428.
2. Berg KA, Maayani S, Goldfarb J, Scaramellini C, Leff P, and Clarke WP (1998) Effector pathway-dependent relative efficacy at serotonin type 2A and 2C receptors: evidence for agonist-directed trafficking of receptor stimulus. Mol Pharmacol 54:94-104. (Pubitemid 28337591)
3. Bhattacharya S, Hall SE, Li H, and Vaidehi N (2008a) Ligand-stabilized conformational states of human beta(2) adrenergic receptor: insight into G-protein-coupled receptor activation. Biophys J 94:2027-2042.
4. Bhattacharya S, Hall SE, and Vaidehi N (2008b) Agonist-induced conformational changes in bovine rhodopsin: insight into activation of G-protein-coupled receptors. J Mol Biol 382:539-555.
5. Bhattacharya S, Subramanian G, Hall S, Lin J, Laoui A, and Vaidehi N (2010) Allosteric antagonist binding sites in class B GPCRs: corticotropin receptor 1. J Comput Aided Mol Des 24:659-674.
6. Bhattacharya S and Vaidehi N (2010) Computational mapping of the conformational transitions in agonist selective pathways of a G-protein coupled receptor. J Am Chem Soc 132:5205-5214.
7. Brewster WK, Nichols DE, Riggs RM, Mottola DM, Lovenberg TW, Lewis MH, and Mailman RB (1990) trans-10,11-dihydroxy-5,6,6a,7,8,12b-hexahydrobenzo[a-] phenanthridine: a highly potent selective dopamine D1 full agonist. J Med Chem 33:1756-1764. (Pubitemid 20180639)
8. Brown JT, Kant A, and Mailman RB (2009) Rapid, semi-automated, and inexpensive radioimmunoassay of cAMP: application in GPCR-mediated adenylate cyclase assays. J Neurosci Methods 177:261-266.
9. Canutescu AA and Dunbrack RL, Jr. (2003) Cyclic coordinate descent: A robotics algorithm for protein loop closure. Protein Sci 12:963-972. (Pubitemid 36505431)
10. Charifson PS, Bowen JP, Wyrick SD, Hoffman AJ, Cory M, McPhail AT, and Mailman RB (1989) Conformational analysis and molecular modeling of 1-phenyl-, 4-phenyl-, and 1-benzyl-1,2,3,4-tetrahydroisoquinolines as D1 dopamine receptor ligands. J Med Chem 32:2050-2058. (Pubitemid 19224165)
11. Cheng Y and Prusoff WH (1973) Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol 22:3099-3108.
12. 2receptors. J Neurochem 59:627-635.
13. Darney KJ Jr, Lewis MH, Brewster WK, Nichols DE, and Mailman RB (1991) Behavioral effects in the rat of dihydrexidine, a high-potency, full-efficacy D1 dopamine receptor agonist. Neuropsychopharmacology 5:187-195.
14. Fiser A and Sali A (2003) Modeller: generation and refinement of homology-based protein structure models. Methods Enzymol 374:461-491. (Pubitemid 37531821)
15. Gay EA, Urban JD, Nichols DE, Oxford GS, and Mailman RB (2004) Functional selectivity of D2 receptor ligands in a Chinese hamster ovary hD2L cell line: evidence for induction of ligand-specific receptor states. Mol Pharmacol 66:97-105. (Pubitemid 38822091)
16. Ghanouni P, Gryczynski Z, Steenhuis JJ, Lee TW, Farrens DL, Lakowicz JR, and Kobilka BK (2001) Functionally different agonists induce distinct conformations in the G protein coupling domain of the beta 2 adrenergic receptor. J Biol Chem 276:24433-24436.
17. Ghosh D, Snyder SE, Watts VJ, Mailman RB, and Nichols DE (1996) 9-Dihydroxy-2,3,7,11b-tetrahydro-1H-naph[1,2,3-de]isoquinoline: a potent full dopamine D1 agonist containing a rigid-beta-phenyldopamine pharmacophore. J Med Chem 39:549-555. (Pubitemid 26041467)
18. Grubbs RA, Lewis MM, Owens-Vance C, Gay EA, Jassen AK, Mailman RB, and Nichols DE (2004) 8,9-dihydroxy-1,2,3,11b-tetrahydrochromeno[4,3,2,-de] isoquinoline (dinoxyline), a high affinity and potent agonist at all dopamine receptor isoforms. Bioorg Med Chem 12:1403-1412. (Pubitemid 38296531)
19. 1 dopamine receptor agonist in a rat model of Parkinson's disease. J Pharmacol Exp Ther 296:338-344.
20. Harper JF and Brooker G (1975) Femtomole sensitive radioimmunoassay for cyclic AMP and cyclic GMP after 2′0 acetylation by acetic anhydride in aqueous solution. J Cyclic Nucleotide Res 1:207-218.
21. Kenakin T (1995) Agonist-receptor efficacy. II. Agonist trafficking of receptor signals. Trends Pharmacol Sci 16:232-238.
22. Kenakin TP (2007) Functional Selectivity through Protean and Biased Agonism: Who Steers the Ship? Mol Pharmacol.
23. Kilts JD, Connery HS, Arrington EG, Lewis MM, Lawler CP, Oxford GS, O'Malley KL, Todd RD, Blake BL, Nichols DE, et al. (2002) Functional selectivity of dopamine receptor agonists. II. Actions of dihydrexidine in D2L receptor-transfected MN9D cells and pituitary lactotrophs. J Pharmacol Exp Ther 301:1179-1189. (Pubitemid 34595112)
24. Lan H, Liu Y, Bell MI, Gurevich VV, and Neve KA (2009a) A dopamine D2 receptor mutant capable of G protein-mediated signaling but deficient in arrestin binding. Mol Pharmacol 75:113-123.
25. Lan H, Teeter MM, Gurevich VV, and Neve KA (2009b) An intracellular loop 2 amino acid residue determines differential binding of arrestin to the dopamine D2 and D3 receptors. Mol Pharmacol 75:19-26.
26. Lawler CP, Prioleau C, Lewis MM, Mak C, Jiang D, Schetz JA, Gonzalez AM, Sibley DR, and Mailman RB (1999) Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes. Neuropsychopharmacology 20:612-627. (Pubitemid 29189265)
27. Lawler CP, Watts VJ, Booth RG, Southerland SB, and Mailman RB (1994) Discrete functional selectivity of drugs: OPC-14597. A selective antagonist for post-synaptic dopamine D2 receptors (Abstract). Soc Neurosci Abstr 20:525.
28. Lovenberg TW, Brewster WK, Mottola DM, Lee RC, Riggs RM, Nichols DE, Lewis MH, and Mailman RB (1989) Dihydrexidine, a novel selective high potency full dopamine D-1 receptor agonist. Eur J Pharmacol 166:111-113. (Pubitemid 19183821)
29. Mailman RB (2007) GPCR functional selectivity has therapeutic impact. Trends Pharmacol Sci 28:390-396.
30. Mansour A, Meng F, Meador-Woodruff JH, Taylor LP, Civelli O, and Akil H (1992) Site-directed mutagenesis of the human dopamine D2 receptor. Eur J Pharmacol 227:205-214.
31. McDonald IK and Thornton JM (1994) Satisfying hydrogen bonding potential in proteins. J Mol Biol 238:777-793. (Pubitemid 24168633)
32. Milligan G (1999) Signal Transduction: A Practical Approach, Oxford University Press, New York.
33. 2 receptors (Abstract). Soc Neurosci Abstr 17:818.
34. Mottola DM, Kilts JD, Lewis MM, Connery HS, Walker QD, Jones SR, Booth RG, Hyslop DK, Piercey M, Wightman RM, et al. (2002) Functional selectivity of dopamine receptor agonists. I. Selective activation of postsynaptic dopamine D2 receptors linked to adenylate cyclase. J Pharmacol Exp Ther 301:1166-1178. (Pubitemid 34595111)
35. Mottola DM, Laiter S, Watts VJ, Tropsha A, Wyrick SD, Nichols DE, and Mailman RB (1996) Conformational analysis of D1 dopamine receptor agonists: pharmacophore assessment and receptor mapping. J Med Chem 39:285-296. (Pubitemid 26027034)
36. Neve KA (2009) Functional Selectivity of G Protein-Coupled Receptor Ligands, Humana Press, New York.
37. Nichols DE (1983) The development of novel dopamine agonists, in Dopamine Receptors (Kaiser C and Kebabian JW eds) pp 201-218, American Chemical Society, Washington DC.
38. Ryman-Rasmussen JP, Nichols DE, and Mailman RB (2005) Differential activation of adenylate cyclase and receptor internalization by novel dopamine D1 receptor agonists. Mol Pharmacol 68:1039-1048. (Pubitemid 41345795)
39. Shapiro DA, Renock S, Arrington E, Chiodo LA, Liu LX, Sibley DR, Roth BL, and Mailman R (2003) Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology 28:1400-1411. (Pubitemid 41070874)
40. Shi L and Javitch JA (2002) The binding site of aminergic G protein-coupled receptors: the transmembrane segments and second extracellular loop. Annu Rev Pharmacol Toxicol 42:437-467. (Pubitemid 34162546)
41. Smith HP, Nichols DE, Mailman RB, and Lawler CP (1997) Locomotor inhibition, yawning and vacuous chewing induced by a novel dopamine D2 post-synaptic receptor agonist. Eur J Pharmacol 323:27-36. (Pubitemid 27136434)
42. Strader CD, Candelore MR, Hill WS, Sigal IS, and Dixon RA (1989) Identification of two serine residues involved in agonist activation of the beta-adrenergic receptor. J Biol Chem 264:13572-13578. (Pubitemid 19198437)
43. Swaminath G, Deupi X, Lee TW, Zhu W, Thian FS, Kobilka TS, and Kobilka B (2005) Probing the beta2 adrenoceptor binding site with catechol reveals differences in binding and activation by agonists and partial agonists. J Biol Chem 280:22165-22171. (Pubitemid 40827872)
44. Tschammer N, Bollinger S, Kenakin T, and Gmeiner P (2011) Histidine 6.55 is a major determinant of ligand-biased signaling in dopamine D2L receptor. Mol Pharmacol 79:575-585.
45. Urban JD, Clarke WP, von Zastrow M, Nichols DE, Kobilka B, Weinstein H, Javitch JA, Roth BL, Christopoulos A, Sexton PM, et al. (2007) Functional selectivity and classical concepts of quantitative pharmacology. J Pharmacol Exp Ther 320:1-13. (Pubitemid 46025713)
46. Vaidehi N and Kenakin T (2010) The role of conformational ensembles of seven transmembrane receptors in functional selectivity. Curr Opin Pharmacol 10:775-781.
47. Versteeg HH, Nijhuis E, van den Brink GR, Evertzen M, Pynaert GN, van Deventer SJ, Coffer PJ, and Peppelenbosch MP (2000) A new phosphospecific cell-based ELISA for p42/p44 mitogen-activated protein kinase (MAPK), p38 MAPK, protein kinase B and cAMP-response-element-binding protein. Biochem J 350:717-722.
48. Warne T, Moukhametzianov R, Baker JG, Nehmé R, Edwards PC, Leslie AG, Schertler GF, and Tate CG (2011) The structural basis for agonist and partial agonist action on a beta(1)-adrenergic receptor. Nature 469:241-244.
49. Wieland K, Zuurmond HM, Krasel C, IJzerman AP, and Lohse MJ (1996) Involvement of Asn-293 in stereospecific agonist recognition and in activation of the beta 2-adrenergic receptor. Proc Natl Acad Sci USA 93:9276-9281. (Pubitemid 26282054)
50. Wiens BL, Nelson CS, and Neve KA (1998) Contribution of serine residues to constitutive and agonist-induced signaling via the D2S dopamine receptor: evidence for multiple, agonist-specific active conformations. Mol Pharmacol 54:435-444. (Pubitemid 28368834)
51. Woodward R, Coley C, Daniell S, Naylor LH, and Strange PG (1996) Investigation of the role of conserved serine residues in the long form of the rat D2 dopamine receptor using site-directed mutagenesis. J Neurochem 66:394-402. (Pubitemid 26010805)
52. Zamanakos G (2001) A fast and accurate analytic method for the computation of solvent effects in molecular simulations. PhD dissertation, California Institute of Technology, Pasadena, CA.